Arteriosclerosis in the heart-brain axis and Alzheimer's disease plasma markers in the Rotterdam Study

Anna M Streiber1,2, Julia Neitzel1,2,3, Amber Yaqub2

  • 1Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.

PubMed

Insights

Arteriosclerosis in the heart-brain axis is linked to higher Alzheimer's disease (AD) dementia plasma markers like neurofilament light chain (NfL) and amyloid-beta (Aβ). Managing vascular health is crucial for neurodegenerative disease prevention.

Area of Science:

  • Neuroscience
  • Cardiology
  • Gerontology

Background:

  • Arteriosclerosis in the heart-brain axis is increasingly recognized in Alzheimer's disease (AD) research.
  • Previous studies focused on structural brain changes, leaving the link between arteriosclerosis and blood-based AD biomarkers under-explored.

Purpose of the Study:

  • To comprehensively assess arteriosclerosis across the heart-brain axis.
  • To investigate the association between arteriosclerosis and plasma biomarkers for AD dementia.

Main Methods:

  • Utilized data from 2238 elderly participants in the population-based Rotterdam Study.
  • Quantified arteriosclerosis via CT scans, measuring calcification in coronary, aortic arch, carotid (extracranial and intracranial), and vertebrobasilar arteries.
  • Analyzed plasma levels of total tau, neurofilament light chain (NfL), and amyloid-beta (Aβ40, Aβ42, Aβ42/40 ratio).

Main Results:

  • A higher arteriosclerosis burden correlated with elevated plasma marker concentrations, particularly for NfL and Aβ40.
  • Intracranial carotid artery calcification showed significant associations with higher NfL and Aβ40 levels.
  • Vertebrobasilar artery calcification was consistently linked to increased total tau levels.

Conclusions:

  • Findings highlight the significant role of vascular health in neurodegenerative processes.
  • Emphasize the importance of monitoring and managing arteriosclerosis for AD dementia prevention and care.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
38
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260